A 6-Week, Randomised, Open-Label, Parallel Group, Multi-Centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Non-Diabetic Metabolic Syndrome Subjects With Raised LDL-C [low-density lipoprotein cholesterol].

Trial Profile

A 6-Week, Randomised, Open-Label, Parallel Group, Multi-Centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Non-Diabetic Metabolic Syndrome Subjects With Raised LDL-C [low-density lipoprotein cholesterol].

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2011

At a glance

  • Drugs Atorvastatin; Rosuvastatin
  • Indications Hypercholesterolaemia; Metabolic syndrome
  • Focus Therapeutic Use
  • Acronyms ROMEO
  • Sponsors AstraZeneca
  • Most Recent Events

    • 14 Jun 2009 Results were presented at the 15th International Symposium on Atherosclerosis (ISA) in Boston, Massachusetts.
    • 11 Sep 2008 Actual end date changed from Jun 2008 to Aug 2008 as reported by Clinicaltrials.gov.
    • 23 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top